Discovery Cohort
We conducted a prospective, open label, randomized cross-over study to assess the effects of antiplatelet therapy (non-enteric coated aspirin 81 mg/day, aspirin 325 mg/day, and ticagrelor 90 mg twice daily) on platelet function and gene expression as previously described.[19] The results of aspirin exposure are presented here. The Supplemental Methods provides more details of inclusion/exclusion criteria. The Duke Institutional Review Board approved the study protocol.